These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 28425805)

  • 1. Study on COgnition and Prognosis in the Elderly (SCOPE): Design and Objectives.
    Hansson L
    Blood Press; 2000; 9(sup1):59. PubMed ID: 28425805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study on COgnition and Prognosis in the Elderly (SCOPE).
    Hansson L; Lithell H; Skoog I; Baro F; Bánki CM; Breteler M; Carbonin PU; Castaigne A; Correia M; Degaute JP; Elmfeldt D; Engedal K; Farsang C; Ferro J; Hachinski V; Hofman A; James OF; Krisin E; Leeman M; de Leeuw PW; Leys D; Lobo A; Nordby G; Olofsson B; Zanchetti A
    Blood Press; 1999; 8(3):177-83. PubMed ID: 10595696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study on COgnition and Prognosis in the Elderly (SCOPE): baseline characteristics.
    Hansson L; Lithell H; Skoog I; Baro F; Bánki CM; Breteler M; Castaigne A; Correia M; Degaute JP; Elmfeldt D; Engedal K; Farsang C; Ferro J; Hachinski V; Hofman A; James OF; Krisin E; Leeman M; de Leeuw PW; Leys D; Lobo A; Nordby G; Olofsson B; Opolski G; Prince M; Reischies FM
    Blood Press; 2000; 9(2-3):146-51. PubMed ID: 10855739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.
    Lithell H; Hansson L; Skoog I; Elmfeldt D; Hofman A; Olofsson B; Trenkwalder P; Zanchetti A;
    J Hypertens; 2003 May; 21(5):875-86. PubMed ID: 12714861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing cardiovascular morbidity and mortality in the elderly.
    Trenkwalder P
    Blood Press Suppl; 2000; 1():40-3. PubMed ID: 11059636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Candesartan Cilexetil, a Novel Angiotensin II Antagonist, Provides Dose-dependent Antihypertensive Effect with Maintained Tolerability.
    Elmfeldt D; George M; Hübner R; Olofsson B
    Blood Press; 2000; 9(sup1):54. PubMed ID: 28425799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive Effects and Tolerability of Candesartan Cilexetil in an Elderly Population.
    Jonker J; McInnes GT
    Blood Press; 2000; 9(sup1):58. PubMed ID: 28425807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducing Cardiovascular Morbidity and Mortality in the Elderly.
    Trenkwalder P
    Blood Press; 2000; 9(sup1):40-43. PubMed ID: 28425804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
    Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD;
    Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Candesartan Cilexetil, 16 mg, Provides a Greater Antihypertensive Effect than Losartan, 50 mg, in Patients with Mild to Moderate Hypertension.
    Neldam S; Andersson OK
    Blood Press; 2000; 9(sup1):55. PubMed ID: 28425797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Combination of Candesartan Cilexetil/hydrochlorothiazide (HCTZ), 8/12.5 mg, has a Similar Antihypertensive Efficacy and is Better Tolerated than Lisinopril/HCTZ, 10/12.5 mg.
    T McINNES G; Istad H; Keinänen-Kiukaanniemi S; VAN Mierlo HFCM
    Blood Press; 2000; 9(sup1):61. PubMed ID: 28425809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of angiotensin II receptor blockers alone and in combination with other drugs: a large clinical experience trial.
    Weir MR; Wang RY
    J Renin Angiotensin Aldosterone Syst; 2001 Mar; 2(1_suppl):S217-S222. PubMed ID: 28095219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension.
    Fogari R; Mugellini A; Derosa G;
    J Renin Angiotensin Aldosterone Syst; 2007 Sep; 8(3):139-44. PubMed ID: 17907102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
    Baguet JP; Nisse-Durgeat S; Mouret S; Asmar R; Mallion JM
    Int J Clin Pract; 2006 Apr; 60(4):391-8. PubMed ID: 16620350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE).
    Skoog I; Lithell H; Hansson L; Elmfeldt D; Hofman A; Olofsson B; Trenkwalder P; Zanchetti A;
    Am J Hypertens; 2005 Aug; 18(8):1052-9. PubMed ID: 16109319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of three months' treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients.
    Strutz F; Bramlage P; Paar WD
    Curr Med Res Opin; 2005 Sep; 21(9):1433-40. PubMed ID: 16197662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Hypertension Optimal Treatment study and the importance of lowering blood pressure.
    Hansson L
    J Hypertens Suppl; 1999 Feb; 17(1):S9-13. PubMed ID: 10340838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization.
    Lithell H; Hansson L; Skoog I; Elmfeldt D; Hofman A; Olofsson B; Trenkwalder P; Zanchetti A;
    J Hypertens; 2004 Aug; 22(8):1605-12. PubMed ID: 15257185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.
    Lacourcière Y; Poirier L; Hebert D; Assouline L; Stolt P; Rehel B; Khder Y
    Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.